Debiopharm, Yale University sign licensing pact

Debio 1036 is an orally available small molecule that antagonizes a key mediator in the inflammation process.

The tie up aims at developing inhibitors targeting a fundamental inflammatory pathway, which plays essential roles in myriad diseases progression and severity

Yale University president Richard Levin said Yale is delighted to be partnered with Debiopharm to advance this program through the pre-clinical and clinical development process.

"We sincerely believe this agreement represents the beginning of a long and fruitful relationship between Yale and Debiopharm for both Debio 1036 and other programs at Yale," Levin said.